1
|
Peña M, Martin A, Holland P, Black LE, Peterman J, Montoya-Williams D, Burris H, Ciara N, Wooten J, Christ L, Walker W, Lilley J, Tkacs M, Scott L. Qualitative analysis of black birthing parents’ influences on infant feeding. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00554-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
2
|
Sun F, Abravan A, McWilliam A, Banfill K, Lilley J, Wheller B, Corinne F, Franks K. PO-1154 Respiratory admissions following RT in relation to pulmonary function and lung doses in lung cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07605-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Davey A, van Herk M, Faivre-Finn C, Lilley J, Sun F, Franks K, McWilliam A. OC-0640 Dose-density interaction predicts local relapse and distant metastasis following lung SABR. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06996-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Hatton N, Saha A, Beasley M, Franks K, Clarke K, Jain P, Teo M, Murray P, Lilley J, Dickinson P. MA03.09 Can Clinical Variables be used to Provide Better Follow up in Stereotactic Ablative Radiotherapy (SABR) Treated Lung Cancers? J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Slevin F, Beasley M, Speight R, Lilley J, Murray L, Hawkins M, Radhakrishna G, Henry A. Evaluation of Clinician Contouring for Pancreatic Stereotactic Ablative Radiotherapy During a Contouring Workshop Organised by the Royal College of Radiologists. Clin Oncol (R Coll Radiol) 2021; 33:e196-e197. [PMID: 33129654 DOI: 10.1016/j.clon.2020.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 10/19/2020] [Indexed: 11/22/2022]
Affiliation(s)
| | - M Beasley
- Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - R Speight
- Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - J Lilley
- Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | | | - M Hawkins
- Medical Physics and Biochemical Engineering, University College London, London, UK
| | | | - A Henry
- University of Leeds, Leeds, UK
| |
Collapse
|
6
|
Fernandez S, Beasley M, Lilley J, Murray L, Short SC. Establishing a Link Between Commonly Reported Toxicities and Tumour Location in Brain Tumour Patients Treated With Volumetric-modulated Arc Radiotherapy. Clin Oncol (R Coll Radiol) 2021; 33:e97-e98. [PMID: 33020010 DOI: 10.1016/j.clon.2020.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Accepted: 09/18/2020] [Indexed: 11/28/2022]
Affiliation(s)
- S Fernandez
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - M Beasley
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - J Lilley
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - L Murray
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - S C Short
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
7
|
Saha A, Hatton N, Beasley M, Franks K, Jain P, Teo M, Clarke K, Dickinson P, Murray P, Lilley J. PO-1007: Predictors of radiation pneumonitis in early stage lung cancer treated with SABR. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01024-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Sun F, Franks K, Murray L, Lilley J, Wheller B, Banfill K, McWilliam A, Abravan A, Van Herk M, Faivre-Finn C, Cubbon R. Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported? Lung Cancer 2020; 146:1-5. [PMID: 32460218 DOI: 10.1016/j.lungcan.2020.05.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 04/18/2020] [Accepted: 05/04/2020] [Indexed: 11/27/2022]
Abstract
BACKGROUND Lung cancer is the most common malignancy worldwide. Radical radiotherapy is an essential treatment in the management of early and locally advanced lung cancer. Cardiac events are known to occur following radical radiotherapy for lung cancer. This study examines the burden of cardiac events post radiotherapy, and estimates the accuracy of death certification in patients who received radical radiotherapy for lung cancer. METHODS We conducted a retrospective observational cohort study for all patients receiving radical radiotherapy for non-small cell lung cancer (NSCLC) at a large cancer centre between 01/01/2010 to 31/12/2016. Baseline cardiovascular disease and cancer status and treatment data were collected, along with hospital admission data and documented cause of death from the national registry for a median follow-up period of 34 months. RESULTS Of 1224 patients included in the analysis, 378 (30.9%) patients had cardiovascular disease at baseline, including 140 (11.4%) with prior myocardial infarction. In the 846 patients without known cardiovascular disease, 451 (53.3%) had a QRISK2 predicted 10-year cardiovascular risk >20% over 10 years. During follow-up, 215 hospitalisations occurred (Incidence rate 6.2 per hundred patient years) which were classified as primarily cardiac, and 622 patients died (18 per 100 patient-years). However, death certificates stated a primary cardiac cause of death in only 33 cases (5.3% of deaths). Notably, 29% of patients dying out of hospital and certified as cancer death did not have documented cancer relapse prior to death, and 61% had no community palliative care input prior to death, implying these events may have been sudden and unexpected. CONCLUSION There is a high prevalence of baseline cardiovascular disease in people undergoing radiotherapy for NSCLC, accompanied by significant rates of post-radiotherapy cardiovascular hospitalisation. However, only a small proportion of deaths are attributed to cardiovascular disease, together with the large amount of sudden deaths observed, this suggests that cardiovascular death is greatly under-reported in official statistics.
Collapse
Affiliation(s)
- F Sun
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - K Franks
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - L Murray
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - J Lilley
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - B Wheller
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - K Banfill
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - A McWilliam
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - A Abravan
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | - M Van Herk
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| | | | - R Cubbon
- Leeds Cancer Centre, Beckett Street, Leeds, UK.
| |
Collapse
|
9
|
Banfill K, Sun F, Mcwilliam A, Abravan A, Lilley J, Wheller B, Schmitt M, Franks K, Van Herk M, Faivre-Finn C. P1.16-20 Trial in Progress: Cardiac Toxicity in Patients Undergoing Curative Intent Radiotherapy for Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Sun F, Murray L, Lilley J, Banfill K, Wheller B, Mcwilliam A, Abravan A, Van Herk M, Faivre-Finn C, Franks K. P1.17-22 Do Statins Improve Outcomes After Radical Radiotherapy for Lung Cancer? An In-Depth Analysis of Over 1100 Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Nix M, Ward G, Goody R, Lilley J, Casanova N, Garratt R, Picken K, Al-Qaisieh B. EP-1954 The role of 4D cone beam CT and abdominal compression in motion management for Liver SABR. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32374-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Nix M, Gregory S, Aldred M, Aspin L, Al-Qaisieh B, Lilley J, Appelt A, Dickinson P, Murray L. PO-1001 Combined image-based and biomechanical deformable image registration of extreme anatomical changes. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31421-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Sun F, Banfill K, Lilley J, Wheller B, Murray L, McWilliam A, Van Herk M, Abravan A, Faivre-Finn C, Franks K. Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz064.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Murray L, Gregory S, Nix M, Aldred M, Aspin L, Uzan J, Lilley J, Al-Qaisieh B, Appelt A. PV-0427 Improving cumulative dose evaluation for reirradiation: first results from the STRIDeR project. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30847-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Slevin F, Beasley M, Needham A, Lilley J, Speight R, Murray L, Henry A. PV-0578 Image quality of cone beam CT used as image-guidance for pelvic Stereotactic Ablative Radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30998-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Banfill K, Sun F, Mcwilliam A, Abravan A, Lilley J, Wheller R, Falk S, Schmitt M, Van Herk M, Franks K, Faivre-Finn C. Avoiding cardiac toxicity in patients undergoing curative intent radiotherapy for lung cancer. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30263-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Christophides D, Gilbert A, Appelt A, Lilley J, Sebag-Montefiore D. PO-0905: Data mining for pre-plan evaluation of organ at risk priority. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31215-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Heijmen B, Bonomo P, Goldner G, Henry A, Lohr F, Simontacchi G, Voet P, Fransen D, Penninkhof J, Milder M, Akhiat A, Casati M, Georg D, Lilley J, Marrazzo L, Pallotta S, Pellegrini R, Seppenwoolde Y, Steil V, Stieler F, Wilson S, Breedveld S. OC-0299: Inconsistencies in clinicians‘ final treatment plan evaluations – a need for automation support. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30609-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
19
|
Christophides D, Gilbert A, Appelt A, Fenwick J, Lilley J, Sebag-Montefiore D. OC-0255: Practical use of principal component analysis in radiotherapy planning. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30698-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Appelt A, Teo M, Christophides D, Peters F, Lilley J, Spindler K, Marijnen C, Sebag-Montefiore D. EP-1748: Mesorectal-only irradiation for early stage rectal cancer: Target volumes and dose to organs at risk. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32111-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Robinson M, Christophides D, Cooper R, Murray P, Lilley J, Muirhead R, Sebag-Montefiore D, Hawkins M. Personalized Dose Escalation in Anal Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Naisbit M, Ward G, Lilley J. EP-1813: Clinical implementation of an adaptive planning technique for lung VMAT radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33064-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
23
|
Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru HB, Needham A, Turner R, Sangha V, Flatley M, Franks K. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort. Clin Oncol (R Coll Radiol) 2015; 28:4-12. [PMID: 26474546 DOI: 10.1016/j.clon.2015.09.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 09/01/2015] [Accepted: 09/08/2015] [Indexed: 11/13/2022]
Abstract
AIMS To report outcomes for the first UK cohort treated for early stage peripheral lung cancer using stereotactic ablative radiotherapy (SABR). MATERIALS AND METHODS Patients were included who received SABR between May 2009 and May 2012. Electronic medical records were reviewed for baseline characteristics, treatment details and outcomes. Patients were treated according to the UK SABR Consortium Guidelines. Univariate and multivariate Cox regression was used to determine factors that influenced overall survival and local control. RESULTS In total, 273 patients received SABR for 288 lesions in the time period examined. The median follow-up was 19.7 months. The median overall survival for all patients was 27.3 months, with 1, 2 and 3 year overall survival of 78.0, 54.9 and 38.6%, respectively. The 1, 2 and 3 year rates of local control were 98.2, 95.7 and 95.7%, respectively. All patients completed the planned course of treatment and rates of Common Toxicity Criteria grade 3+ toxicity were low. On multivariate analysis, patients with Medical Research Council (MRC) breathlessness scores of 3-5 had worse overall survival compared with patients with scores of 1-2 (hazard ratio: 2.10; 95% confidence interval: 1.25-3.59) and the presence of histological diagnosis conferred improved overall survival (hazard ratio: 0.54; 95% confidence interval: 0.31-0.93), probably reflecting that patients who are considered well enough to undergo biopsy are generally fitter overall. No factors were identified that significantly influenced local control. CONCLUSIONS SABR is an effective and well-tolerated treatment option for patients with early stage peripheral lung cancer who are not suitable for surgery. No patient cohort was identified in whom SABR was considered inappropriate. This series adds to the existing positive data that support SABR for this patient group.
Collapse
Affiliation(s)
- L Murray
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - S Ramasamy
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - J Lilley
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - M Snee
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - K Clarke
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - H B Musunuru
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - A Needham
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - R Turner
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - V Sangha
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - M Flatley
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK
| | - K Franks
- St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK.
| |
Collapse
|
24
|
Harding R, Trnková P, Weston SJ, Lilley J, Thompson CM, Short SC, Loughrey C, Cosgrove VP, Lomax AJ, Thwaites DI. Benchmarking of a treatment planning system for spot scanning proton therapy: comparison and analysis of robustness to setup errors of photon IMRT and proton SFUD treatment plans of base of skull meningioma. Med Phys 2015; 41:111710. [PMID: 25370624 DOI: 10.1118/1.4897571] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Base of skull meningioma can be treated with both intensity modulated radiation therapy (IMRT) and spot scanned proton therapy (PT). One of the main benefits of PT is better sparing of organs at risk, but due to the physical and dosimetric characteristics of protons, spot scanned PT can be more sensitive to the uncertainties encountered in the treatment process compared with photon treatment. Therefore, robustness analysis should be part of a comprehensive comparison between these two treatment methods in order to quantify and understand the sensitivity of the treatment techniques to uncertainties. The aim of this work was to benchmark a spot scanning treatment planning system for planning of base of skull meningioma and to compare the created plans and analyze their robustness to setup errors against the IMRT technique. METHODS Plans were produced for three base of skull meningioma cases: IMRT planned with a commercial TPS [Monaco (Elekta AB, Sweden)]; single field uniform dose (SFUD) spot scanning PT produced with an in-house TPS (PSI-plan); and SFUD spot scanning PT plan created with a commercial TPS [XiO (Elekta AB, Sweden)]. A tool for evaluating robustness to random setup errors was created and, for each plan, both a dosimetric evaluation and a robustness analysis to setup errors were performed. RESULTS It was possible to create clinically acceptable treatment plans for spot scanning proton therapy of meningioma with a commercially available TPS. However, since each treatment planning system uses different methods, this comparison showed different dosimetric results as well as different sensitivities to setup uncertainties. The results confirmed the necessity of an analysis tool for assessing plan robustness to provide a fair comparison of photon and proton plans. CONCLUSIONS Robustness analysis is a critical part of plan evaluation when comparing IMRT plans with spot scanned proton therapy plans.
Collapse
Affiliation(s)
- R Harding
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdomand Abertawe Bro Morgannwg University Health Board, Medical Physics and Clinical Engineering, Swansea SA2 8QA, United Kingdom
| | - P Trnková
- Paul Scherrer Institute, Centre for Proton Therapy, Villigen 5232, Switzerland
| | - S J Weston
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdom
| | - J Lilley
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdom
| | - C M Thompson
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdom
| | - S C Short
- Leeds Institute of Molecular Medicine, Oncology and Clinical Research, Leeds LS9 7TF, United Kingdomand St James's Institute of Oncology, Oncology, Leeds LS9 7TF, United Kingdom
| | - C Loughrey
- St James's Institute of Oncology, Oncology, Leeds LS9 7TF, United Kingdom
| | - V P Cosgrove
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdom
| | - A J Lomax
- Paul Scherrer Institute, Centre for Proton Therapy, Villigen 5232, Switzerland
| | - D I Thwaites
- St James's Institute of Oncology, Medical Physics and Engineering, Leeds LS9 7TF, United Kingdomand Institute of Medical Physics, School of Physics, University of Sydney, Sydney NSW 2006, Australia
| |
Collapse
|
25
|
Murray L, Thompson C, Lilley J, Cosgrove V, Franks K, Sebag-Montefiore D, Henry A. Risk of Second Malignancy Following Prostate Radiation Therapy Using Contemporary Radiation Therapy Techniques. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Hammond L, Lilley J, Pope G, Ribbans W. EVALUATING INFLUENCES ON CLASSIFICATIONS OF SEVERITY FOR INJURIES IN PROFESSIONAL FOOTBALL. Br J Sports Med 2014. [DOI: 10.1136/bjsports-2014-093494.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Ramasamy S, Musunuru H, Sangha V, Flatley M, Spencer K, Turner R, Stuart R, Clarke K, Needham A, Lilley J, Snee M, Franks K. 171 Lung stereotactic ablative radiotherapy (SABR) for medically inoperable peripheral Stage I NSCLC at the St. James's Institute of Oncology. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70172-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Musunuru H, Junni P, Smith D, Lilley J, Wilson S, Swift S, Carey B, Crellin A, Sebag-Montefiore D, Radhakrishna G. EP-1246: Effect of duodenal overlap volume with PTV (Duo OLV) in locally advanced pancreatic cancer radiotherapy planning. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31364-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Murray L, Thompson C, Lilley J, Franks K, Sebag-Montefiore D, Henry A. OC-0077: Risk of second malignancy following prostate radiotherapy using modern radiotherapy techniques. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30182-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Choong E, Ramasamy S, Musunuru H, Jain P, Needham A, Lilley J, Turner R, Snee M, Clarke K, Franks K. 164 Thoracic stereotactic body radiotherapy (SABR) in patients who previously had curative treatment for lung cancer. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70165-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Murray L, Lilley J, Thompson C, Sykes J, Franks K, Sebag-Montefiore D, Cosgrove V, Henry A. Isotoxic Simultaneous Integrated Boost to Dominant Intraprostatic Lesions Using Stereotactic Ablative Radiation Therapy and Volumetric Modulated Arc Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Paynter D, Derbyshire S, Lilley J, Weston S, Thompson C, Cosgrove V, Thwaites D. PO-0827: Elekta AgilityTM FFF for Lung VMAT SABR. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33133-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Baker A, Clark C, Ciurlionis L, Distefano G, Hatton M, Jain P, Lilley J, Mayles H, Miles E, Scott A, Webster G. 177 Clinical implementation of stereotactic ablative radiotherapy (SABR) for NSCLC in the UK. Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70177-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Lilley J, Derbyshire S, Thompson C, Franks K, Cosgrove V. VMAT for Lung SABR With a New 160 Leaf MLC. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.2207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
Speight R, Franks K, Henry A, Casanova N, Cosgrove V, Lilley J. Producing a VMAT Class Solution for Adjuvant Pelvic Radiation Therapy for Penile Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Musunuru H, Lilley J, Naisbit M, Ramasamy S, Kirwin S, Snee M, Clarke K, Turner R, Stuart R, Franks K. PD-0290 CORRELATION BETWEEN DOSE VOLUME PARAMETERS AND TOXICITY IN PATIENTS TREATED WITH SABR FOR STAGE 1 LUNG CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70629-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Speight R, Lilley J, Derbyshire S, Orton J, Cooper R. EP-1524 IMPLEMENTATION OF ELEKTA VMAT FOR ENDOMETRIUM PATIENTS USING ONCENTRA MASTERPLAN. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71857-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Thompson C, Dunning J, Bowden J, Sen M, Prestwich R, Lilley J. EP-1551 A PROSPECTIVE STUDY OF VMAT SOLUTIONS FOR UNILATERAL HEAD AND NECK TUMOURS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71884-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Needham A, Summers H, Sykes D, Lilley J, Henry D, Franks D. OC-0233 RADIATION TECHNOLOGIST LED IMAGE GUIDED RADIOTHERAPY – IS IT SAFE AND ACHIEVABLE FOR LUNG SBRT? Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70572-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Derbyshire S, Thompson C, Franks K, Lilley J. PO-0926 ELEKTA VMAT WITH MONACO FOR LUNG SBRT. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71259-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Harding R, Lilley J, Cosgrove V, Weston S, Thompson C, Sykes J, Thwaites D. PO-0930 ROBUSTNESS OF IMPT (INTENSITY MODULATED PROTON THERAPY) COMPARED WITH IMRT FOR HEAD AND NECK CANCERS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71263-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Radhakrishna G, collins M, Wilson S, Sebag-Montefiore D, Carey B, Swift S, Franks K, Lilley J, Smith D, Kirwin S, Lindsay R, Summers H, Woolley A, Byrne P, Roberts N, Sykes J, Needham A, Crellin A. 936 poster DOSE ESCALATION STUDY USING 4D CT PLANNING IN LOCALLY ADVANCED PANCREATIC CANCER. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71058-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Lilley J, Derbyshire S, Cosgrove V, Thompson C, Thwaites D. 1383 poster VERIFICATION DOSIMETRY FOR LUNG SBRT VMAT. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71505-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
44
|
Needham A, Lindsay R, Sykes J, Lilley J, Franks K, Summers H, Wooley A. 4D Cone Beam CT for Online Verification of Lung Stereotactic Body Radiotherapy at the St James's Institute of Oncology (SJIO). Clin Oncol (R Coll Radiol) 2011. [DOI: 10.1016/j.clon.2011.01.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Derbyhire S, Lilley J, Cosgrove V, Thompson C, Bowden J, Henry A, Franks K, Thwaites D. Clinical Implementation of Elekta VMAT. Clin Oncol (R Coll Radiol) 2011. [DOI: 10.1016/j.clon.2011.01.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Sangha V, Prestwich R, Lilley J, Needham A, Summers H, Stuart R, Turner R, Bond M, Snee M, Franks K. Feasibility and Early Outcomes of Stereotactic Radiotherapy in Early Lung Cancer at St James's Institute of Oncology. Clin Oncol (R Coll Radiol) 2011. [DOI: 10.1016/j.clon.2011.01.476] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Jain P, Franks K, Lilley J, Landau D, Mohammed N, Peedell C, Hatton M. 97 Implementation of stereotactic body radiotherapy (SBRT) for non-small cell lung cancers in the UK: update from the SBRT Consortium. Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70097-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Sangha V, Prestwich R, Lilley J, Needham A, Summers H, Turner R, Snee M, Franks K. 114 Lung stereotactic body radiotherapy (SBRT) for medically inoperable peripheral stage 1 non-small cell lung cancer (NSCLC): updated results from St James's Institute of Oncology, Leeds. Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70114-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Jain P, Franks K, Peedell C, Lilley J, Landau D, Faivre-Finn C, Hatton M. Implementation of stereotactic body radiotherapy (SBRT) for non small cell lung cancers in the UK. Lung Cancer 2010. [DOI: 10.1016/s0169-5002(10)70105-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Hammond LE, Lilley J, Ribbans WJ. Coding sports injury surveillance data: has version 10 of the Orchard Sports Injury Classification System improved the classification of sports medicine diagnoses? Br J Sports Med 2008; 43:498-502. [PMID: 19050000 DOI: 10.1136/bjsm.2008.051979] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To compare versions 8 and 10 of the Orchard Sports Injury Classification System (OSICS) to determine whether the revised version of OSICS has improved its use in a sports medicine setting, and to assess the inter-rater reliability of OSICS-10. METHODS Injury surveillance data, gathered over a 2 year period in professional football, cricket and rugby union to produce 335 diagnoses, were coded with both OSICS-8 and OSICS-10. Code-diagnosis agreement was assessed for OSICS-8 in terms of whether a diagnosis was codeable or noncodeable, and for OSICS-10 by evaluating the highest available OSICS-10 tier of coding. Eight clinicians coded a list of 20 diagnoses, comprising a range of pathologies to all gross anatomical regions, which were compared to assess inter-rater reliability. RESULTS All diagnoses could be assigned an appropriate code with OSICS-10, compared with 87% of diagnoses that could be assigned an OSICS-8 code. Contusions comprised almost half of OSICS-8 noncodeable diagnoses. OSICS-10 tier 2 codes accounted for 20% of diagnoses coded with the updated system. Of these 20%, almost half contained a more detailed diagnosis that did not have an available OSICS-10 tier 3 or 4 code. Inter-rater reliability increased with decreasing diagnostic detail, with an overall level shown to be moderate (k = 0.56). CONCLUSIONS OSICS-10 is a more encompassing system than OSICS-8 to use in classifying sports medicine diagnoses, and has a moderate level of inter-rater reliability. Further minor revision may be required to address lack of detail in some strain, effusion and contusion codes.
Collapse
Affiliation(s)
- L E Hammond
- University of Nottingham, Division of Rehabilitation and Ageing, B Floor, The Medical School, Queens Medical Centre, Nottingham, NG7 2UH.
| | | | | |
Collapse
|